Johnson & Johnson’s affiliate, Janssen Therapeutics, Division of Janssen Products, LP, has signed a memorandum of understanding (MOU) representing the intention of the company along with the United States Agency for International Development (USAID) to step up the fight against the health threat of antibiotic-resistant bacteria, specifically for multidrug-resistant tuberculosis (MDR-TB).

Under the MOU, Janssen would contribute an estimated $30 million worth of its anti-MDR-TB treatment, about 30,000 courses. USAID will work with its implementing partners, national TB programs, and with Janssen to ensure responsible access and appropriate use of the treatment. This commitment builds upon and strengthens the company's agreement with the Stop TB Partnership's Global Drug Facility to facilitate access to quality-assured medicines in more than 100 countries worldwide. Over the coming months, Janssen and USAID will engage with the global TB community to solicit support, develop eligibility criteria,and engage others to help address this public health crisis.

“Despite the development of new MDR-TB treatment options, the ability to scale up the appropriate use of treatment regimens remains very challenging given weak health care infrastructures, which typically exist in vulnerable countries,” said the company in a statement.”However, in order to prevent further resistance, it is essential to ensure responsible access to new treatment options in these countries, including accurate diagnosis and documentation of use and impact.”

Source: Johnson & Johnson